Top Markets
Coin of the day
Marizyme, Inc. Marizyme, Inc.

Marizyme, Inc.

MRZM
Rangering i aksjer #41141
Marizyme, Inc. is a life sciences company primarily engaged in bringing... Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
Aksjekurs
$0.0003
Sist synkronisert: 2026-08-11
Markedsverdi
$39.54K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Marizyme, Inc. (MRZM)

Kategori

Utbytteavkastning for Marizyme, Inc. (MRZM)
Marizyme, Inc. (aksjesymbol: MRZM) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Marizyme, Inc. (MRZM) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter